Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine

1. Turk S, Turk C, Malkan UY, et al. Current community trans - mission and future perspectives on the COVID-19 process. Turk J Med Sci 51: 1001-1011, 2021.
2. Atay MH, Okuyucu M, Gullu YT, et al. Clinical course of Cov- id-19 in hematological disorders. UHOD-Int J Hematol Oncol 31: 153-160, 2021.
3. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol 42 Suppl 1: 11-18, 2020.
4. Ropa J, Cooper S, Capitano ML, Broxmeyer HE. Sars-Cov-2 Spike Protein Induces Cellular Changes in primitive and ma - ture hematopoietic cells. Blood 136: 25-26, 2020.
5. Haznedaroglu IC, Beyazit Y. Local bone marrow renin-angi - otensin system in primitive, definitive and neoplastic haemat- opoiesis. Clin Sci (Lond) 124: 307-323, 2013.
6. Heringer-Walther S, Eckert K, Schumacher SM, et al. Angio - tensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 94: 857-860, 2009.
7. Ratajczak MZ, Bujko K, Ciechanowicz A, et al. SARS-CoV-2 entry receptor ACE2 is expressed on very small CD45- precursors of hematopoietic and endothelial cells and in re - sponse to virus spike protein activates the Nlrp3 inflamma - some. Stem Cell Reviews and Reports 17: 266-277, 2021.
8. Jiang H, Mei YF. SARS-CoV-2 Spike Impairs DNA damage repair and inhibits V(D)J recombination in vitro. Viruses 13: 2056-2066, 2021.
9. Ropa J, Cooper S, Capitano ML, et al. Human hematopoi - etic stem, progenitor, and immune cells respond Ex Vivo to SARS-CoV-2 Spike Protein. Stem Cell Rev Rep 17: 253-265, 2021.
10. Ratajczak MZ, Kucia M. SARS-CoV-2 infection and overacti- vation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells. Leu - kemia. 34: 1726-1729, 2020.

APA	erdoğdu b, Çınar O, Malkan U, AKSU S, Demiroglu H, Buyukasik Y, Göker H, Sayinalp N, Haznedaroglu I (2022). Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. , 65 - 67. 10.4999/uhod.226097
Chicago	erdoğdu batuhan,Çınar Olgu Erkin,Malkan Umit Yavuz,AKSU SALIH,Demiroglu Haluk,Buyukasik Yahya,Göker Hakan,Sayinalp Nilgun,Haznedaroglu Ibrahim C. Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. (2022): 65 - 67. 10.4999/uhod.226097
MLA	erdoğdu batuhan,Çınar Olgu Erkin,Malkan Umit Yavuz,AKSU SALIH,Demiroglu Haluk,Buyukasik Yahya,Göker Hakan,Sayinalp Nilgun,Haznedaroglu Ibrahim C. Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. , 2022, ss.65 - 67. 10.4999/uhod.226097
AMA	erdoğdu b,Çınar O,Malkan U,AKSU S,Demiroglu H,Buyukasik Y,Göker H,Sayinalp N,Haznedaroglu I Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. . 2022; 65 - 67. 10.4999/uhod.226097
Vancouver	erdoğdu b,Çınar O,Malkan U,AKSU S,Demiroglu H,Buyukasik Y,Göker H,Sayinalp N,Haznedaroglu I Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. . 2022; 65 - 67. 10.4999/uhod.226097
IEEE	erdoğdu b,Çınar O,Malkan U,AKSU S,Demiroglu H,Buyukasik Y,Göker H,Sayinalp N,Haznedaroglu I "Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine." , ss.65 - 67, 2022. 10.4999/uhod.226097
ISNAD	erdoğdu, batuhan vd. "Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine". (2022), 65-67. https://doi.org/10.4999/uhod.226097

APA	erdoğdu b, Çınar O, Malkan U, AKSU S, Demiroglu H, Buyukasik Y, Göker H, Sayinalp N, Haznedaroglu I (2022). Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. Uluslararası Hematoloji-Onkoloji Dergisi, 32(1), 65 - 67. 10.4999/uhod.226097
Chicago	erdoğdu batuhan,Çınar Olgu Erkin,Malkan Umit Yavuz,AKSU SALIH,Demiroglu Haluk,Buyukasik Yahya,Göker Hakan,Sayinalp Nilgun,Haznedaroglu Ibrahim C. Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. Uluslararası Hematoloji-Onkoloji Dergisi 32, no.1 (2022): 65 - 67. 10.4999/uhod.226097
MLA	erdoğdu batuhan,Çınar Olgu Erkin,Malkan Umit Yavuz,AKSU SALIH,Demiroglu Haluk,Buyukasik Yahya,Göker Hakan,Sayinalp Nilgun,Haznedaroglu Ibrahim C. Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. Uluslararası Hematoloji-Onkoloji Dergisi, vol.32, no.1, 2022, ss.65 - 67. 10.4999/uhod.226097
AMA	erdoğdu b,Çınar O,Malkan U,AKSU S,Demiroglu H,Buyukasik Y,Göker H,Sayinalp N,Haznedaroglu I Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. Uluslararası Hematoloji-Onkoloji Dergisi. 2022; 32(1): 65 - 67. 10.4999/uhod.226097
Vancouver	erdoğdu b,Çınar O,Malkan U,AKSU S,Demiroglu H,Buyukasik Y,Göker H,Sayinalp N,Haznedaroglu I Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine. Uluslararası Hematoloji-Onkoloji Dergisi. 2022; 32(1): 65 - 67. 10.4999/uhod.226097
IEEE	erdoğdu b,Çınar O,Malkan U,AKSU S,Demiroglu H,Buyukasik Y,Göker H,Sayinalp N,Haznedaroglu I "Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine." Uluslararası Hematoloji-Onkoloji Dergisi, 32, ss.65 - 67, 2022. 10.4999/uhod.226097
ISNAD	erdoğdu, batuhan vd. "Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine". Uluslararası Hematoloji-Onkoloji Dergisi 32/1 (2022), 65-67. https://doi.org/10.4999/uhod.226097